Search

Your search keyword '"De Carli É"' showing total 9 results
Start Over Author "De Carli É"
9 results on '"De Carli É"'

1. Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program

Author

Di Carlo, D., Annereau, M., Vignes, M., Denis, L., Epaillard, N., Dumont, S., Guyon, D., Rieutord, A., Jacobs, S., Salomon, V., Yoldjian, I., Duperray, F., Brunel, L., Baiao, X., Lemos, F., Vauleon, E., Capra, M., Abbou, S., Touat, M., Sanson, M., Gandemer, V., De Carli, E., Bourdeaut, F., Hezam, I., Vassal, G., and Grill, J.

Published
2025
Full Text
View/download PDF

2. A model for Hopfions on the space-time S^3 x R

Author

De Carli, E. and Ferreira, L. A.

Subjects
High Energy Physics - Theory, Mathematical Physics, Nonlinear Sciences - Exactly Solvable and Integrable Systems
Abstract

We construct static and time dependent exact soliton solutions for a theory of scalar fields taking values on a wide class of two dimensional target spaces, and defined on the four dimensional space-time S^3 x R. The construction is based on an ansatz built out of special coordinates on S^3. The requirement for finite energy introduces boundary conditions that determine an infinite discrete spectrum of frequencies for the oscillating solutions. For the case where the target space is the sphere S^2, we obtain static soliton solutions with non-trivial Hopf topological charges. In addition, such hopfions can oscillate in time, preserving their topological Hopf charge, with any of the frequencies belonging to that infinite discrete spectrum., Comment: Enlarged version with the time-dependent solutions explicitly given. One reference and two eps figures added. 14 pages, latex

Published
2004
Full Text
View/download PDF

9. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.

Author

Chaix J, Schleiermacher G, Corradini N, André N, Thebaud E, Gambart M, Defachelles AS, Entz-Werle N, Chastagner P, De Carli É, Ducassou S, Landman-Parker J, Adam-de-Beaumais T, Larive A, Michiels S, Vassal G, Valteau-Couanet D, Geoerger B, and Berlanga P

Subjects
Humans, Prospective Studies, Chronic Disease, Recurrence, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Neuroblastoma drug therapy, Neuroblastoma genetics
Abstract

Introduction: Despite poor survival for patients with relapsed or refractory neuroblastoma, only 10-16% of patients are reported to be included in early phase trials. This study aimed to explore the impact of molecular profiling within the prospective precision cancer medicine trial MAPPYACTS (NCT02613962) on subsequent early phase trial recruitment and treatment by matched targeted therapies in this population., Methods and Materials: Clinical data from all French patients with relapsed/refractory neuroblastoma enrolled in MAPPYACTS were analyzed for subsequent matched/non-matched targeted treatment based on clinical tumor board (CMTB) recommendations., Results: From 93 patients with neuroblastoma included in French centers, 78 (84%) underwent whole exome and RNA sequencing and were discussed in the CMTB. Higher rate of successful sequencing analysis was observed in patients with relapsed disease compared to those with refractory disease (p = 0.0002). Among the 50 patients that presented with a new disease relapse/progression after the CMTB recommendations, 35 patients (70%) had at least one actionable alteration identified on the tumor at the time of relapse. Eighteen patients (36%) were included in an early phase clinical trial, 11 of these with a matched agent, 7 with a non-matched treatment; 13 patients were included in the AcSé ESMART trial. Five patients (10%) received a matched targeted therapy outside a clinical trial., Conclusion: Patients with neuroblastoma in the European MAPPYACTS trial were more likely to be included in early phase trials compared to previous reports. Early deep sequencing at first treatment failure, comprehensive therapeutic discussions in molecular tumor boards and innovative trials like AcSé -ESMART improve access to innovative therapies for patients with relapsed/refractory neuroblastoma., Clinical Trial Registration: NCT02613962., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results